Medications for Steroid Resistant Acute Graft Versus Host Disease

1 result
  • jakafi

    (ruxolitinib)
    Incyte Corporation
    Jakafi is indicated for treating intermediate or high-risk myelofibrosis, polycythemia vera in adults intolerant to hydroxyurea, and steroid-refractory acute and chronic graft-versus-host disease in patients aged 12 and older who have not responded to prior systemic therapies.